Company Overview of Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule compounds that target P2X3 receptors for the treatment of chronic pain, respiratory, and urological conditions. Its products include AF-219 that is used for patients with osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis/bladder pain syndrome; and AF-220, a second-generation P2X3 antagonist. The company was founded in 2009 and is based in San Mateo, California.
2929 Campus Drive
San Mateo, CA 94403
Founded in 2009
Key Executives for Afferent Pharmaceuticals, Inc.
Co-Founder and Chief Scientific Officer
Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.
Afferent Pharmaceuticals, Inc. Key Developments
Afferent Pharmaceuticals Elects K. Peter Hirth as Board of Director
Dec 3 14
Afferent Pharmaceuticals announced the election of K. Peter Hirth, Ph.D., to Afferent's Board of Directors. Dr. Hirth has more than 30 years of drug discovery and development experience in the biotechnology and pharmaceutical industries, and has built several successful biotech companies. Dr. Hirth co-founded Plexxikon Inc., with operations starting in 2001 and serving as CEO until May 2013. During Dr. Hirth's tenure, Plexxikon discovered and advanced several NCEs to the clinic in a variety of indications, including a selective BRAF inhibitor approved by the FDA and sold under the brand name ZelborafTM along with a companion diagnostic. Plexxikon was acquired by Daiichi Sankyo in 2011. Prior to this, Dr. Hirth was president of SUGEN, Inc.
Afferent Pharmaceuticals, Inc. Announces Executive Changes
Sep 10 14
Afferent Pharmaceuticals, Inc. announced that Kathleen Sereda Glaub has been named as Chief Executive Officer. Ms. Glaub had been serving as an independent member of Afferent's Board since 2013, and she will continue to serve on the Board. She is replacing Bruce G. McCarthy, M.D., who served as the company's CEO since 2009. Prior to joining Afferent, Ms. Glaub most recently co-led Plexxikon Inc. as President.
Afferent Pharmaceuticals, Inc. Announces Management Appointments
Nov 6 13
Afferent Pharmaceuticals announced that Michael M. Kitt, M.D., has been named to the newly created position of Chief Medical Officer, effective immediately. In addition, Afferent announced the appointment of Kathleen Sereda Glaub to the Company's Board of Directors, expanding the number of Company directors to six. Dr. Kitt has over 30 years' experience in drug development with a proven record of success in running clinical trial programs and taking compounds through to NDA approval. He most recently served as Senior Vice President, Clinical Research and Regulatory Affairs and Chief Medical Officer at Portola Pharmaceuticals, Inc., where he led the planning and initiation of an international Phase 3 clinical program for the company's lead product candidate. Ms. Glaub has over 30 years of management and company-building experience for biopharma and innovation-based companies. Most recently, she co-led Plexxikon Inc. as President, a position she held for 12 years. During her tenure, Ms. Glaub was responsible for the business and financing strategy of the company leading its venture and partnership transactions, and ultimately leading the sale of the company to Daiichi Sankyo for nearly $1 billion in 2011. She also played a pivotal role in the company's product development programs, including the development of the company's melanoma drug Zelboraf and its companion diagnostic. She also put in place the commercial infrastructure and sales force to support the co-promotion of Zelboraf for the product launch in 2011.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 1, 2015